CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
B-cell lymphoma, Leukemia |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase Ⅰ |
The First Affiliated Hospital of Nanchang University |
Multiple myeloma (MM) |
Details
|
CD19 CAR-T cell therapy (National University of Malaysia) |
|
Phase Ⅲ |
National University of Malaysia |
Acute lymphoblastic leukaemia (ALL) |
Details
|
MC-19PD1 CAR-T cell therapy (Peking University) |
|
Phase Ⅰ |
Peking University |
B-cell lymphoma |
Details
|
ALLO-501 |
ALLO-501 |
Phase Ⅰ |
Cellectis, Allogene Therapeutics, Servier |
Diffuse large B cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase Ⅰ |
Hrain Biotechnology |
Lymphoblastic leukaemia |
Details
|
AUTO-3 |
AUTO-3,AUTO3 |
Phase Ⅱ |
University College London, Autolus |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) |
|
Phase Ⅰ |
Institute of Hematology & Blood Diseases Hospital, Zhongyuan Union Cell&Gene Engineering Corp.,Ltd |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19 chimeric antigen receptor T cell therapy (Takara Bio) |
TBI-1501 |
Phase Ⅱ |
TaKaRa Bio, Memorial Sloan-Kettering Cancer Center |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) |
|
Phase Ⅰ |
Fred Hutchinson Cancer Research Center |
Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL), Non-Hodgkin B-cell lymphomas |
Details
|
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.) |
|
Phase Ⅰ |
HeBei Yanda hospital, China Immunotech Co., Ltd |
B-cell lymphoma |
Details
|
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore) |
|
Phase Ⅰ |
National University Health System, Singapore |
Acute lymphoblastic leukaemia (ALL) |
Details
|
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase Ⅰ |
Marino Biotechnology, Chengdu Galaxy Biomed, Peking University |
B-cell lymphoma |
Details
|
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital) |
|
Phase Ⅱ |
Beijing Boren Hospital |
Acute lymphoblastic leukaemia (ALL) |
Details
|
NI-204 |
AP-101-Neurimmune; TDI-200; NI-204A |
Preclinical |
Neurimmune, ALS Therapy Development Institute |
Amyotrophic lateral sclerosis (ALS) |
Details
|
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source) |
|
Phase Ⅰ |
Nonindustrial source |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) |
LCAR-L10D |
Phase Ⅰ |
Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech |
Diffuse large B cell lymphoma |
Details
|
SGN-CD19B |
SGN-CD19B |
Phase Ⅰ |
Seattle Genetics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
GC-007F (Gracell Biotechnology) |
GC-007F |
Phase Ⅰ |
Gracell Biotechnology |
B-cell lymphoma |
Details
|
Taplitumomab paptox |
|
Phase Ⅲ |
University of Minnesota |
Leukemia |
Details
|
aCD19z |
aCD19z |
Phase Ⅰ |
Christie Hospital NHS Foundation Trust, Cellular Therapeutics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19 and CD22 targeted CAR-T cell therapy (Chongqing Xinqiao Hospital) |
|
Phase Ⅰ |
Chongqing Xinqiao Hospital |
B-cell lymphoma |
Details
|
C-CAR011 |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army, Cellular Biomedicine Group, Shanghai saibiman biotechnology |
Lymphoblastic leukaemia, Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Leukemia, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase Ⅰ |
Seattle Children's Hospital |
Solid tumours, Cancer |
Details
|
GC-012F |
GC-012F |
Phase Ⅰ |
Gracell Biotechnology |
Multiple myeloma (MM) |
Details
|
GC007g |
GC-007G,GC007G |
Phase Ⅰ |
Gracell Biotechnology |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) |
|
Phase Ⅰ |
Memorial Sloan-Kettering Cancer Center |
Acute lymphoblastic leukaemia (ALL) |
Details
|
pCAR-19B |
|
Phase Ⅰ |
Chongqing Precision Biotech |
Lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) |
yinnuokati-19 |
Phase Ⅱ |
Shenzhen Institute for Innovation and Translational Medicine, Dongguan People's Hospital |
Chronic lymphocytic leukemia (CLL), Lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19CAR |
CD19CAR |
Phase Ⅰ |
City of Hope National Medical Center, National Cancer Institute |
Lymphomatoid granulomatosis, Hairy cell leukemia, Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) |
|
Phase Ⅲ |
Chaim Sheba Medical Center at Tel HaShomer |
Acute myeloid Leukemia (AML) |
Details
|
GTB-1550 |
DT-2219ARL; DT-2219; IND-100780; OXS-1550 |
Phase Ⅱ |
University of Minnesota, Oxis International, GT Biopharma |
B-cell lymphoma, Leukemia |
Details
|
TAK-007 |
TAK-007,TAK 007 |
Phase Ⅱ |
University of Texas M. D. Anderson Cancer Center, Takeda |
B-cell lymphoma |
Details
|
Senl-1904A |
Senl-1904A; Senl_1904A |
Phase Ⅰ |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
Lymphoblastic leukaemia |
Details
|
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) |
WZTL002-1 |
Phase Ⅰ |
Malaghan Institute of Medical Research |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Primary mediastinal B cell lymphoma, Follicular lymphoma, Non-Hodgkin B-cell lymphomas |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase Ⅱ |
M.D. Anderson Cancer Center |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase Ⅰ |
University of Texas Southwestern Medical Center, Galileo Research |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
YTB-323 |
YTB-323 |
Phase Ⅰ |
Novartis |
Small lymphocytic lymphoma (SLL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL) |
Details
|
PF-6883541 |
PF-06883541; PF-6883541 |
Phase Ⅰ |
Pfizer, Allogene Therapeutics |
Solid tumours |
Details
|
AUTO-1 |
AUTO1; AUTO-1 |
Phase Ⅱ |
University College London, Autolus |
Acute lymphoblastic leukaemia (ALL) |
Details
|
GNC-038 |
GNC-038 |
IND Filing |
Sichuan Baili Pharmaceutical |
Hematological cancer |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) |
|
Phase Not Specified |
Nanjing CART Medical Technology |
B-cell malignancies |
Details
|
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) |
|
Phase Ⅱ |
Shanghai GeneChem |
Leukemia, Systemic lupus erythematosus |
Details
|
CD19-CART |
|
Phase Ⅱ |
Shanghai Hrain Biotechnology |
Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) |
|
Phase Ⅰ |
Chongqing Xinqiao Hospital |
B-cell lymphoma, B-cell Acute Lymphoblastic Leukemia |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
B-cell lymphoma, Leukemia |
Details
|
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) |
|
Phase Ⅱ |
Wuhan Sian Medical Technology, Wuhan Union Hospital, Jingzhou Central Hospital, Xiangyang Central Hospital, The First People's Hospital of Yuhang District |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology) |
|
Phase Ⅰ |
Gracell Biotechnology |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase Ⅰ |
City of Hope National Medical Center |
Non-Hodgkin's lymphoma (NHL) |
Details
|
AFM-11 |
AFM-11 |
Phase Ⅰ |
Affimed |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CC-97540 |
CC-97540 |
Phase Ⅰ |
Juno Therapeutics |
Non-Hodgkin B-cell lymphomas |
Details
|
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase Ⅰ |
iCarTAB Biomed |
Leukemia, Lymphoma |
Details
|
B-193 |
B-193 |
Preclinical |
Shanghai Yanyi Biotechnology, Buchang Pharma |
Cancer |
Details
|
BinD-19 (Shenzhen BinDeBio) |
BinD-19 |
IND Filing |
BinDeBio |
Lymphoblastic leukaemia, B-cell lymphoma |
Details
|
CLBR-001/SWI-019 |
CLBR-001/SWI-019 |
Phase Ⅰ |
Abbvie, California Institute for Biomedical Research |
B-cell lymphoma |
Details
|
CLIC-1901 (Ottawa Hospital Research Institute) |
CLIC-1901 |
Phase Ⅱ |
Ottawa Hospital Research Institute |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase Ⅰ |
UCLAs Jonsson Comprehensive Cancer Center |
Chronic lymphocytic leukemia (CLL), B-cell lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Shanghai Children's Medical Center) |
|
Phase Ⅱ |
Miltenyi Biotec, Shanghai Children's Medical Center |
Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-19,4SCAR19,4SCAR 19 |
Phase Ⅱ |
Shenzhen Geno-Immune Medical Institute |
B-cell lymphoma |
Details
|
IM19CAR-T |
|
Phase Ⅱ |
Beijing Immunochina Medical Science & Technology |
Leukemia, Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19 CARvac T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
B-cell malignancies |
Details
|
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) |
|
Phase Not Specified |
Leidos |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) |
PZ-01 |
Phase Not Specified |
Pinze Lifetechnology |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
3rd-gen-CD19-CAR |
3rd-gen-CD19-CAR |
Phase Ⅱ |
bluebird bio, Celgene |
B-cell lymphoma, Leukemia |
Details
|
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) |
BPX-401,BPX 401,BPX401 |
Phase Ⅱ |
Bellicum, Ospedale Pediatrico Bambino Gesu |
Leukemia, Lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) |
|
Phase Ⅰ |
HeBei Yanda hospital, China Immunotech Co., Ltd |
B-cell lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase Ⅱ |
The First Affiliated Hospital of Nanchang University |
Lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase Ⅰ |
Shanghai Longyao Biotechnology |
Acute lymphoblastic leukaemia (ALL) |
Details
|
GNR-084 |
GNR-084 |
Phase Ⅰ |
GENERIUM Pharmaceuticals, IONTAS |
B-cell lymphoma |
Details
|
CART-19 cells (Henan Hualong Biotechnology) |
|
Phase Ⅱ |
Henan Hualong Biotechnology |
Lymphoblastic leukaemia |
Details
|
CD19 CAR-T cell (Pregene) |
|
Phase Ⅱ |
Pregene |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
FH-2494 |
FH-2494 |
Phase Ⅱ |
Fred Hutchinson Cancer Research Center, National Cancer Institute |
Leukemia, Lymphoma |
Details
|
MDX 1342 |
MDX-1342 |
Phase Ⅰ |
Medarex |
Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA) |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase Ⅰ |
Seattle Children's Hospital |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR T-cell therapy (University College London) |
4G7-CARD |
Phase Ⅰ |
University College London |
Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) |
XLCART-001 |
Phase Ⅱ |
Nanjing Medical University |
B-cell lymphoma |
Details
|
RO-7227166 |
RO-7227166 |
Phase Ⅰ |
Roche |
Non-Hodgkin's lymphoma (NHL) |
Details
|
A-319 |
A-319,A319 |
Phase Ⅰ |
Generon Corporation |
B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase Ⅱ |
Soochow University |
Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
B-cell lymphoma |
Details
|
Oncolysin B |
|
Phase Ⅲ |
ImmunoGen |
Leukemia, Lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19.CAR T Cells (University Hospital Heidelberg) |
|
Phase Ⅱ |
University of Heidelberg |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) |
|
Phase Ⅰ |
Nagoya University, Shinshu University, Japan Tissue Engineering, Fujifilm group |
Acute lymphoblastic leukaemia (ALL) |
Details
|
BZ019 |
BZ-019 |
Phase Ⅰ |
Shanghai Cell Therapy Research Institute |
Diffuse large B cell lymphoma, Primary mediastinal B cell lymphoma, Follicular lymphoma |
Details
|
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy |
GC-197 |
Phase Ⅱ |
Gracell Biotechnology |
B-cell lymphoma, B-Cell Leukemia |
Details
|
Tafasitamab |
MOR-208; MOR-00208; XENP-5574; XmAb-5574 |
BLA Filing |
Xencor, MorphoSys |
Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase Ⅰ |
Immune Cell, Weifang People's Hospital |
Lymphoblastic leukaemia, B-cell lymphoma |
Details
|
K193 bispecific antibody |
K-193 |
Phase Ⅰ |
Beijing Luzhu Biotechnology |
B-cell lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) |
|
Phase Ⅱ |
Shanghai Bioray Laboratory Inc |
Leukemia |
Details
|
TC-110 |
TC-110 |
Phase Ⅱ |
TCR2 Therapeutics |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Primary mediastinal B cell lymphoma, Follicular lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
TAC01-CD19 |
TAC01-CD19 |
Phase Ⅱ |
Triumvira Immunologics |
B-cell lymphoma |
Details
|
CD19 CAR-T (HuaDao CAR-Tcell) |
|
Phase Ⅰ |
HuaDao CAR-Tcell |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
JCAR-015 |
JCAR-15; JCAR-015; 19-28z CAR T cells; 19-28z+ T cells; 19-28z-T-Cells |
Phase Ⅱ |
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene, TaKaRa Bio |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase Ⅰ |
Shanghai Jiaotong University |
Acute lymphoblastic leukaemia (ALL) |
Details
|
HuCART19 |
|
Phase Ⅱ |
Kite Pharma, National Cancer Institute |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Denintuzumab mafodotin |
SGN-19A; SGN-CD19A |
Phase Ⅱ |
Seattle Genetics |
Diffuse large B cell lymphoma, Follicular lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
CTL-119 |
CTL-119 |
Phase Ⅱ |
University of Pennsylvania, Novartis |
Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Multiple myeloma (MM), Acute lymphoblastic leukaemia (ALL) |
Details
|
ICT19G1 |
ICT-19G1 |
Phase Ⅰ |
Innovative Cellular Therapeutics |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
Phase Ⅰ |
Fujian Medical University |
Diffuse large B cell lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) |
|
Phase Ⅱ |
Hrain Biotechnology, Fudan University Zhongshan Hospital |
Diffuse large B cell lymphoma, Follicular lymphoma |
Details
|
4G7SDIE |
|
Phase Not Specified |
Synimmune, The University of Tubingen |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Coltuximab ravtansine |
SAR-3419; huB4-DM4 |
Phase Ⅱ |
ImmunoGen, Sanofi |
Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
AMG-562 |
AMG-562 |
Phase Ⅰ |
Amgen |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase Ⅱ |
Southwest Hospital Chongqing |
Diffuse large B cell lymphoma |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase Ⅰ |
Tianjin Mycure Medical Technology |
Acute lymphoblastic leukaemia (ALL) |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
Multiple myeloma (MM), Lymphoma |
Details
|
GB5005 chimeric antigen receptor T cell therapy(Genbase) |
GB-5005 |
IND Filing |
Genbase |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine) |
|
Phase Ⅱ |
Shanghai Unicar-Therapy Bio-medicine Technology |
Non-Hodgkin's lymphoma (NHL) |
Details
|
19-28z+ |
19-28z+ |
Phase Ⅱ |
Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute |
Leukemia |
Details
|
UCART-19 |
UCART-19; S-68587 |
Phase Ⅰ |
Cellectis, Pfizer, Servier |
Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL) |
Details
|
CD19-CAR |
CD19-CAR |
Phase Ⅰ |
M.D. Anderson Cancer Center, Ziopharm Oncology, Intrexon Corporation |
Leukemia, Lymphoma |
Details
|
CD19.CAR-VST |
CD19.CAR-VST |
Phase Ⅰ |
Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase Ⅰ |
Stanford University |
B-cell lymphoma |
Details
|
TI-1007 |
TI-1007,TI 1007,TI1007 |
Phase Ⅱ |
Timmune Biotech |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) |
|
IND Filing |
Unicar-Therapy Bio-medicine Technology |
Lymphoma |
Details
|
CTA-101 |
CTA-101 |
Phase Ⅰ |
Nanjing Bioheng Biotech, Xuzhou Medical University (XZMU), Nanjing Medical University |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Virus-specific-CD19.CAR |
|
Phase Ⅰ |
Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System |
Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 CAR-T cell therapy (Juventas) |
CNCT19,CNCT-19,HY001 |
Phase Ⅰ |
Juventas |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
MB-CART2019.1 |
MB-CART2019.1 |
Phase Ⅱ |
Miltenyi Biotec |
Small lymphocytic lymphoma (SLL), Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) |
|
Phase Ⅰ |
Kecellitics Biotech Company Ltd |
Leukemia, Lymphoma |
Details
|
JWCAR-029 |
JWCAR-029,JWCAR029; JWCAR 029 |
BLA Filing |
Shanghai Mingju Biological Technology |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) |
|
Phase Ⅰ |
Juno Therapeutics |
hematological malignancies |
Details
|
JCAR-014 |
JCAR-014 |
Phase Ⅱ |
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
XYF19 CAR-T cell therapy (Xijing Hospital) |
|
Phase Ⅰ |
Xijing Hospital |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Bioceltech) |
|
Phase Not Specified |
Bioceltech Therapeutics |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T cell therapy (Uppsala University) |
|
Phase Ⅱ |
Uppsala University |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) |
|
Phase Ⅰ |
Kunming Medical University |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase Ⅱ |
Southwest Hospital Chongqing |
Diffuse large B cell lymphoma |
Details
|
ET190L1-ARTEMIS T cells (Eureka Therapeutics) |
ET-190; ET190; ET190L1; ET190L1-ARTEMI |
Phase Ⅰ |
Eureka therapeutics, Duke University |
Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) |
SENL-B19 |
Phase Ⅱ |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
B-cell lymphoma, hematological malignancies, Acute lymphoblastic leukaemia (ALL) |
Details
|
Monoclonal antibody B43 Genistein-conjugate |
|
Phase Ⅰ |
University of Minnesota, Bristol-Myers Squibb |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
|
Phase Ⅱ |
Medical College of Wisconsin |
B-cell malignancies |
Details
|
DI-B4 |
DI-B4 |
Phase Ⅰ |
Cancer Research UK, Merck Serono |
B-cell lymphoma, Chronic lymphocytic leukemia (CLL) |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Yake) |
YK-C19 |
Phase Not Specified |
Yake Biotechnology |
Lymphoblastic leukaemia, B-cell lymphoma |
Details
|
Lisocabtagene maraleucel (Celgene/Juno Therapeutics) |
JCAR-017; Liso-Cel |
BLA Filing |
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene |
Non-Hodgkin's lymphoma (NHL) |
Details
|
anti-CD19 CAR T-cell (Henan Cancer Hospital) |
|
Phase Ⅱ |
Henan Cancer Hospital, Pregene |
Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase Ⅰ |
Henan Cancer Hospital |
B-cell lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Fujian Medical University) |
|
Phase Ⅲ |
Fujian Medical University |
Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center) |
|
Phase Ⅰ |
Fred Hutchinson Cancer Research Center |
B-cell malignancies |
Details
|
CD19/CD3 |
|
Preclinical |
YZY Bio |
Lymphoma |
Details
|
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) |
|
Phase Ⅱ |
Xuanwu Hospital of Capital Medical University |
Acute lymphoblastic leukaemia (ALL) |
Details
|
ET-019002 |
ET-019002 |
Phase Ⅰ |
Eureka therapeutics |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
PTG-01 |
PTG-01 |
Phase Ⅰ |
Protheragen |
Acute lymphoblastic leukaemia (ALL) |
Details
|
EBV-CTL (Atara/MSKCC) |
EBV-CTL-Atara-MSKCC |
Preclinical |
Memorial Sloan-Kettering Cancer Center, Atara Biotherapeutics |
EBV-associated post-transplant lymphoproliferative disease (PTLD) |
Details
|
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase Ⅰ |
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene) |
BG-T19 |
Phase Ⅰ |
Guangzhou Bio-gene Technology |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Obexelimab |
XmAb-5871; AMG-729 |
Phase Ⅲ |
Xencor |
Autoimmune diseases, Systemic lupus erythematosus, Rheumatoid arthritis (RA) |
Details
|
因诺卡替-19细胞 |
|
IND Filing |
Shenzhen Innovation Immunotechnology |
Lymphoblastic leukaemia |
Details
|
CD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust |
|
Phase Ⅰ |
Christie Hospital NHS Foundation Trust, Cancer Research UK, University of Manchester |
Non-Hodgkin B-cell lymphomas |
Details
|
Duvortuxizumab |
JNJ-64052781; MGD-011 |
Phase Ⅰ |
MacroGenics, Janssen |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), hematological malignancies, Follicular lymphoma, Malignancies |
Details
|
Chimeric antigen receptor T-cell therapy (Hebei Senlang Biotechnology) |
Senl_B19 |
Phase Ⅱ |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
hematological malignancies |
Details
|
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) |
|
Phase Ⅰ |
Timmune Biotech |
Non-Hodgkin's lymphoma (NHL) |
Details
|
Loncastuximab tesirine |
ADCT-402 |
Phase Ⅲ |
ADC Therapeutics |
Diffuse large B cell lymphoma |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology) |
|
Phase Ⅰ |
Wuhan Sian Medical Technology |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) |
|
Phase Ⅱ |
University of Alberta |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
U-CART (Shanghai Bioray Laboratory Inc) |
|
Phase Ⅱ |
Shanghai Bioray Laboratory Inc |
hematological malignancies, Acute lymphoblastic leukaemia (ALL) |
Details
|
PBCAR-0191 |
PBCAR-0191 |
Phase Ⅱ |
Baxalta, Precision BioSciences |
Lymphoblastic leukaemia, Non-Hodgkin's lymphoma (NHL) |
Details
|
PCAR-119 (PersonGen Biomedicine) |
PCAR-119,PCAR 119,PCAR119 |
Phase Ⅱ |
PersonGen Biomedicine |
Leukemia, Lymphoma |
Details
|
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase Ⅱ |
National Institute of Allergy and Infectious Diseases, University of Pittsburgh |
Primary humoral immunodeficiency |
Details
|
CAR-T 19 cell therapy (University of Pennsylvania) |
|
Phase Ⅱ |
University of Pennsylvania |
B-cell Acute Lymphoblastic Leukemia |
Details
|
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) |
CARCIK-CD19; CIK-CAR.CD19 |
Phase Ⅱ |
Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
Acute lymphoblastic leukaemia (ALL) |
Details
|
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase Ⅱ |
Wuhan Bio-Raid Biotechnology |
B-cell lymphoma, Haematological disorders |
Details
|
CAR-CD19 T cell therapy |
|
Phase Ⅱ |
CARsgen Therapeutics |
Leukemia, Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 CAR-T cell therapy (Sinobioway) |
|
Phase Ⅱ |
Sinobioway Biomedicine |
Diffuse large B cell lymphoma, Lymphoma |
Details
|
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) |
|
Phase Ⅰ |
Guangzhou Institutes of Biomedicine and Health (GIBH) |
Acute lymphoblastic leukaemia (ALL) |
Details
|
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) |
|
IND Filing |
Unicar-Therapy Bio-medicine Technology |
Acute lymphoblastic leukaemia (ALL), Central nervous system leukemia |
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
Leukemia, Lymphoma |
Details
|
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) |
|
Phase Ⅰ |
HeBei Yanda hospital |
B-cell lymphoma |
Details
|
Senl-1904B |
Senl-1904B; Senl_1904B |
Phase Ⅰ |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
Lymphoblastic leukaemia |
Details
|
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) |
|
Phase Ⅱ |
Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Boston Children's Hospital |
Leukemia |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase Ⅱ |
Innovative Cellular Therapeutics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
CD19 CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase Ⅱ |
Chongqing Precision Biotech |
Chronic B-Cell Lymphocytic Leukemia, Leukemia, Lymphoma, B-Cell Leukemia |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
Phase Not Specified |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
Leukemia |
Details
|
H-31970-SAGAN |
H-31970-SAGAN |
Phase Ⅰ |
Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) |
|
Phase Ⅱ |
Innovative Cellular Therapeutics, Zhejiang University, Kunming Medical University |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Leukemia, Follicular lymphoma |
Details
|
TG-1801 |
TG-1801; NI-1701 |
Phase Ⅰ |
NovImmune, TG Therapeutics |
B-cell lymphoma |
Details
|
PCAR-019 (Anke Biotechnology) |
|
Phase Ⅱ |
Anke Biotechnology |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|